BR122019021332A8 - Processo de síntese de oligômeros de morfolino - Google Patents
Processo de síntese de oligômeros de morfolinoInfo
- Publication number
- BR122019021332A8 BR122019021332A8 BR122019021332A BR122019021332A BR122019021332A8 BR 122019021332 A8 BR122019021332 A8 BR 122019021332A8 BR 122019021332 A BR122019021332 A BR 122019021332A BR 122019021332 A BR122019021332 A BR 122019021332A BR 122019021332 A8 BR122019021332 A8 BR 122019021332A8
- Authority
- BR
- Brazil
- Prior art keywords
- morpholino
- group
- synthesis
- lower alkyl
- protected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98819207P | 2007-11-15 | 2007-11-15 | |
US98820007P | 2007-11-15 | 2007-11-15 | |
PCT/US2008/012804 WO2009064471A1 (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
Publications (2)
Publication Number | Publication Date |
---|---|
BR122019021332A2 BR122019021332A2 (pt) | 2015-05-26 |
BR122019021332A8 true BR122019021332A8 (pt) | 2022-12-06 |
Family
ID=40293764
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122019021332A BR122019021332A8 (pt) | 2007-11-15 | 2008-11-14 | Processo de síntese de oligômeros de morfolino |
BRPI0819828A BRPI0819828A8 (pt) | 2007-11-15 | 2008-11-14 | Processo de síntese de oligômeros de morfolino |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0819828A BRPI0819828A8 (pt) | 2007-11-15 | 2008-11-14 | Processo de síntese de oligômeros de morfolino |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2207779B1 (pt) |
JP (3) | JP5512533B2 (pt) |
KR (1) | KR101617472B1 (pt) |
CN (1) | CN101861318A (pt) |
BR (2) | BR122019021332A8 (pt) |
CA (2) | CA2704261C (pt) |
DK (1) | DK2207779T3 (pt) |
ES (1) | ES2479393T3 (pt) |
HK (1) | HK1144424A1 (pt) |
HR (1) | HRP20140646T1 (pt) |
IL (1) | IL205776A0 (pt) |
MX (1) | MX2010004955A (pt) |
RU (1) | RU2606627C2 (pt) |
WO (1) | WO2009064471A1 (pt) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2010141511A2 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
US8697858B2 (en) | 2009-11-13 | 2014-04-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
KR102182663B1 (ko) | 2010-05-28 | 2020-11-25 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
ES2607603T3 (es) | 2010-09-30 | 2017-04-03 | Nippon Shinyaku Co., Ltd. | Derivado de ácido morfolino nucleico |
EP3067420A1 (en) | 2010-11-12 | 2016-09-14 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
EP2732035A2 (en) | 2011-07-15 | 2014-05-21 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
WO2013074834A1 (en) | 2011-11-18 | 2013-05-23 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
US9944926B2 (en) | 2011-11-30 | 2018-04-17 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
EP2785729B1 (en) | 2011-11-30 | 2020-11-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
TR201809173T4 (tr) | 2011-12-08 | 2018-07-23 | Sarepta Therapeutics Inc | İnsan LMNA'sını hedef alan oligonükleotid analogları. |
KR102071729B1 (ko) * | 2011-12-28 | 2020-01-31 | 니뽄 신야쿠 가부시키가이샤 | 안티센스 핵산 |
WO2013142087A1 (en) | 2012-03-20 | 2013-09-26 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
US9856474B2 (en) | 2013-01-16 | 2018-01-02 | Iowa State University Research Foundation, Inc. | Deep intronic target for splicing correction on spinal muscular atrophy gene |
EP3015467A4 (en) | 2013-05-24 | 2016-11-02 | Ajinomoto Kk | PROCESS FOR THE PRODUCTION OF MORPHOLINO-OLIGONUCLEOTIDE |
CA2922838A1 (en) | 2013-09-05 | 2015-03-12 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
JP6794258B2 (ja) | 2013-09-30 | 2020-12-02 | ジェロン・コーポレーションGeron Corporation | オリゴヌクレオチドについてのホスホロジアミデート骨格結合 |
MY193708A (en) | 2014-03-12 | 2022-10-26 | Nippon Shinyaku Co Ltd | Antisense nucleic acids |
EP3143141B1 (en) | 2014-05-16 | 2019-10-02 | Oregon State University | Antisense antibacterial compounds and methods |
EP3569252B1 (en) | 2014-05-19 | 2021-12-15 | Oregon State University | Antisense antibacterial compounds and methods |
BR112016029369B1 (pt) | 2014-06-17 | 2020-12-08 | Nippon Shinyaku Co., Ltd. | oligômero antissentido, composição farmacêutica uso de um oligômero antissentido ou um sal ou hidrato farmaceuticamente aceitável do mesmo, e, métodos para fabricação e para triagem de um oligômero antissentido |
CN106795186B (zh) | 2014-10-14 | 2021-03-02 | 味之素株式会社 | 吗啉代寡核苷酸的制备方法 |
AU2015372560B2 (en) | 2014-12-31 | 2021-12-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
US10675356B2 (en) | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
WO2016196670A1 (en) | 2015-06-01 | 2016-12-08 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
JP6978406B2 (ja) | 2015-08-05 | 2021-12-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 均質オリゴマーを調製するためのキラル試薬 |
AU2016312530A1 (en) | 2015-08-24 | 2018-03-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
CN108026531B (zh) | 2015-09-15 | 2021-09-14 | 日本新药株式会社 | 反义核酸 |
EP3351634A4 (en) | 2015-09-16 | 2019-05-08 | Nippon Shinyaku Co., Ltd. | ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF AMYOTROPHY |
WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
CN108472504A (zh) | 2015-12-15 | 2018-08-31 | 萨勒普塔医疗公司 | 肽寡核苷酸缀合物 |
EP3394261A4 (en) | 2015-12-23 | 2019-11-27 | Oregon State University | ANTISENSE ANTIBACTERIAL COMPOUNDS AND ASSOCIATED METHODS |
WO2017112888A1 (en) | 2015-12-23 | 2017-06-29 | David Greenberg | Antisense antibacterial compounds and methods |
WO2017184529A1 (en) | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
JP7042255B2 (ja) | 2016-04-29 | 2022-03-25 | サレプタ セラピューティクス, インコーポレイテッド | ヒトlmnaを標的にするオリゴヌクレオチド類縁体 |
EP3463390A1 (en) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics, Inc. | Pharmaceutical composition comprising eteplirsen |
MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
EP3463363A4 (en) | 2016-05-24 | 2020-02-19 | Sarepta Therapeutics, Inc. | METHOD FOR PRODUCING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS |
US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
WO2017205879A2 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
AU2017269355B2 (en) | 2016-05-24 | 2021-04-15 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
WO2017205513A1 (en) * | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
CN116804031A (zh) * | 2016-09-20 | 2023-09-26 | 科罗拉多州立大学董事会法人团体 | 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体 |
MD3554554T2 (ro) | 2016-12-19 | 2022-12-31 | Sarepta Therapeutics Inc | Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară |
NZ755438A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
KR20230110811A (ko) | 2016-12-19 | 2023-07-25 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
US20200362339A1 (en) * | 2017-09-25 | 2020-11-19 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis |
WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
US11560401B2 (en) | 2018-05-10 | 2023-01-24 | Nippon Shinyaku Co., Ltd. | Method for preparing oligonucleic acid compound |
US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
TW202035692A (zh) | 2018-06-26 | 2020-10-01 | 日商日本新藥股份有限公司 | 含有反義寡核苷酸之組成物及其用於治療裘馨氏肌肉萎縮症之用途 |
TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
JP2022511055A (ja) | 2018-12-13 | 2022-01-28 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート |
GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
CN114981281A (zh) | 2019-11-13 | 2022-08-30 | 日本新药株式会社 | 寡核苷酸化合物的制造方法 |
US20230014840A1 (en) | 2019-11-13 | 2023-01-19 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
JPWO2021125311A1 (pt) | 2019-12-19 | 2021-06-24 | ||
JPWO2021132591A1 (pt) | 2019-12-26 | 2021-07-01 | ||
EP4112083A1 (en) | 2020-02-28 | 2023-01-04 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid inducing skipping of exon 51 |
JP2023541091A (ja) * | 2020-07-10 | 2023-09-28 | チャンヂョウ シンザオール ファーマシューティカルズ カンパニー リミテッド | オリゴヌクレオチドを調製するための方法 |
WO2022230954A1 (ja) | 2021-04-28 | 2022-11-03 | 日本新薬株式会社 | オリゴ核酸化合物の製造方法 |
EP4342498A1 (en) | 2021-05-13 | 2024-03-27 | National University Corporation Chiba University | Antisense oligomer |
CN117500925A (zh) | 2021-05-28 | 2024-02-02 | 住友制药株式会社 | 反义核酸 |
JPWO2022270585A1 (pt) | 2021-06-23 | 2022-12-29 | ||
EP4368186A1 (en) | 2021-07-08 | 2024-05-15 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
WO2023282344A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 腎毒性軽減剤 |
IL310001A (en) | 2021-07-08 | 2024-03-01 | Nippon Shinyaku Co Ltd | sediment suppressant |
JPWO2023026994A1 (pt) | 2021-08-21 | 2023-03-02 | ||
WO2023034515A2 (en) | 2021-09-03 | 2023-03-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
CA3233242A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2023167908A1 (en) * | 2022-03-01 | 2023-09-07 | Eisai R&D Management Co., Ltd. | Bis-protected, activated guanine monomers |
WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
CN117586307B (zh) * | 2024-01-19 | 2024-04-16 | 凯莱英生命科学技术(天津)有限公司 | Pmo鸟苷单体的合成方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH577464A5 (pt) * | 1972-09-22 | 1976-07-15 | Ciba Geigy Ag | |
US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
JP3398378B2 (ja) * | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
WO1991018898A1 (fr) * | 1990-06-01 | 1991-12-12 | Nippon Shinyaku Co., Ltd. | Homologue d'acide nucleique |
US5510476A (en) | 1994-07-07 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Carbocation scavenging during oligonucleotide synthesis |
UA48150C2 (uk) * | 1994-11-02 | 2002-08-15 | Ай-Сі-Ен Фармасьютикалз | Похідні амінокислот або аміноспиртів, олігонуклеотид |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
AU2007297861A1 (en) * | 2006-05-10 | 2008-03-27 | Avi Biopharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
-
2008
- 2008-11-14 CA CA2704261A patent/CA2704261C/en active Active
- 2008-11-14 WO PCT/US2008/012804 patent/WO2009064471A1/en active Application Filing
- 2008-11-14 EP EP08850132.5A patent/EP2207779B1/en active Active
- 2008-11-14 CA CA2884340A patent/CA2884340C/en active Active
- 2008-11-14 BR BR122019021332A patent/BR122019021332A8/pt not_active Application Discontinuation
- 2008-11-14 RU RU2010123958A patent/RU2606627C2/ru not_active Application Discontinuation
- 2008-11-14 ES ES08850132.5T patent/ES2479393T3/es active Active
- 2008-11-14 JP JP2010534042A patent/JP5512533B2/ja active Active
- 2008-11-14 DK DK08850132.5T patent/DK2207779T3/da active
- 2008-11-14 BR BRPI0819828A patent/BRPI0819828A8/pt not_active Application Discontinuation
- 2008-11-14 CN CN200880116219A patent/CN101861318A/zh active Pending
- 2008-11-14 KR KR1020107009620A patent/KR101617472B1/ko active IP Right Grant
- 2008-11-14 MX MX2010004955A patent/MX2010004955A/es active IP Right Grant
-
2010
- 2010-05-13 IL IL205776A patent/IL205776A0/en unknown
- 2010-11-18 HK HK10110758.9A patent/HK1144424A1/xx unknown
-
2014
- 2014-03-26 JP JP2014063314A patent/JP6178744B2/ja active Active
- 2014-07-07 HR HRP20140646AT patent/HRP20140646T1/hr unknown
-
2016
- 2016-06-30 JP JP2016129716A patent/JP2016196494A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6178744B2 (ja) | 2017-08-09 |
ES2479393T3 (es) | 2014-07-24 |
DK2207779T3 (da) | 2014-07-14 |
RU2010123958A (ru) | 2011-12-20 |
EP2207779A1 (en) | 2010-07-21 |
RU2606627C2 (ru) | 2017-01-10 |
BRPI0819828A2 (pt) | 2015-05-26 |
WO2009064471A1 (en) | 2009-05-22 |
JP5512533B2 (ja) | 2014-06-04 |
IL205776A0 (en) | 2010-11-30 |
CA2704261C (en) | 2015-05-26 |
MX2010004955A (es) | 2010-06-30 |
BRPI0819828A8 (pt) | 2022-12-27 |
CA2704261A1 (en) | 2009-05-22 |
AU2008321409B2 (en) | 2014-08-14 |
CA2884340C (en) | 2017-07-25 |
AU2008321409A1 (en) | 2009-05-22 |
BR122019021332A2 (pt) | 2015-05-26 |
HK1144424A1 (en) | 2011-02-18 |
JP2014159432A (ja) | 2014-09-04 |
KR20100090681A (ko) | 2010-08-16 |
EP2207779B1 (en) | 2014-04-09 |
HRP20140646T1 (hr) | 2014-09-26 |
CA2884340A1 (en) | 2009-05-22 |
CN101861318A (zh) | 2010-10-13 |
JP2016196494A (ja) | 2016-11-24 |
KR101617472B1 (ko) | 2016-05-02 |
JP2011503184A (ja) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122019021332A8 (pt) | Processo de síntese de oligômeros de morfolino | |
Ju et al. | Nucleotide analogues as inhibitors of SARS‐CoV polymerase | |
ES2528285T3 (es) | Molécula de ácido nucleico monocatenario que tiene esqueleto alicíclico que contiene nitrógeno | |
JP2009524696A5 (pt) | ||
BRPI0717970B8 (pt) | composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto | |
BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
TW200617060A (en) | Copolycarbonates having improved flowability | |
BR0014225A (pt) | Derivados de pirazol | |
BRPI0512060B8 (pt) | compostos orgânicos, composições farmacêuticas compreendendo os mesmos, bem como uso e processo de preparação dos referidos compostos | |
BRPI0517737A (pt) | inibidores de quinase | |
BRPI0900983B8 (pt) | composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso | |
TW200633979A (en) | Method | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
BR0112456A (pt) | Compostos de piperidina para uso como inibidores de ccr-3 | |
CO5271665A1 (es) | (compuestos de pirrolo [2,3-d] pirimidina | |
BRPI0613570B8 (pt) | composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BR0314379A (pt) | Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase | |
BR0313831A (pt) | Sais benzenossulfonato de derivados de 4-flúor-2-cianopirrolidina | |
BRPI1011130A8 (pt) | Composto organometálico, processo de preparação de um composto organometálico,e, utilização de um composto organometálico. | |
SG137667A1 (en) | Highly branched (co)polycarbonates having improved flowability | |
MX2011012631A (es) | Inhibidores de actividad de cinasa tipo pirimidina. | |
BRPI0601766A (pt) | composições contendo aminas e seu uso | |
BR0313727A (pt) | Derivados de isoquinolina como inibidores de metaloproteinase da matriz | |
Pommier et al. | Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site | |
NO20055167L (no) | Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2560 DE 28/01/2020 POR TER SIDO INDEVIDA. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: SAREPTA THERAPEUTICS, INC. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: SAREPTA THERAPEUTICS, INC. (US) |